Business
Anixa Biosciences Announces Presentation at the 2019 San Antonio Breast Cancer Symposium
SAN JOSE, Calif., Dec. 2, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Dec. 2, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data from its ongoing studies utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology will be presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS).\n\n \nThe symposium takes place December 10 – 14, 2019 in San Antonio, TX, and is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease. The meeting will be attended by both U.S. and international researchers and healthcare professionals who are involved in breast cancer research and clinical care. \nPoster presentation details are as follows:\nTitle: Combining HyperVOX with pattern recognition neural networks: A new method for analyzing flow cytometry-based immunophenotyping data for increased early detection of stage I/II breast cancer (BCa)\nAuthors: George A. Dominguez, Ph.D.; John Roop; Alex Polo; Anthony J. Campisi; Dmitry I. Gabrilovich, MD, Ph.D.; Amit Kumar, Ph.D.\nPoster Session and Number: Session 5, P5-01-16\nLocation: Henry B. Gonzalez Convention Center, Hall 1\nDate and Time: Friday, December 13, 2019 (5:00 PM – 7:00 PM CT)\nTo receive a copy of the presentation, please email your request to [email protected] starting December 14, 2019 and include your name, title, and contact information.\nAbout Cchek™Cchek™ is an early cancer detection technology, that measures a patient's immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient's cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa's orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method that offers improved affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek™ to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust c...